




35<sup>TH</sup> ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lutfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org



PRELIMINARY  
SCIENTIFIC PROGRAM

WEDNESDAY, 22 APRIL 2026

LEGEND >>	PLENARY SESSIONS	SCIENTIFIC SESSIONS	PRE-CONGRESS WORKSHOPS	SATELLITE SYMPOSIA	ABSTRACT SESSIONS	GENERAL & SOCIAL		
Time / Room	MAIN HALL 1	HALL 2	HALL 3	HALL 4	HALL 5	HALL 6	HALL 7	HALL 8
8:00-13:40	REGISTRATION							
13:40-15:10	<b>VIRAL HEPATITIS</b> 1. Epidemiology and natural history of hepatitis A virus infection 2. Hepatitis A vaccination and treatment of hepatitis A virus infection 3. Epidemiology and natural history of hepatitis E virus infection 4. Treatment of acute and chronic HEV infection 5. Discussion	<b>BASIC SCIENCES I</b> 1. Functional architecture of the liver during chronic viral hepatitis 2. Regional division of the 3D structure of NASH 3. Differences in structure and function across different regions of the cirrhotic liver 4. Structural heterogeneity of HCC tumors	<b>ENDO-HEPATOLOGY LIVE DEMONSTRATIONS</b> SESSION I: Diagnostic 1. Evaluation of Liver by EUS 2. Evaluation of portal hypertension by EUS 3. Evaluation of Biliary tree by EUS 4. Evaluation of Biliary tree by cholangioscopy	<b>CHALLENGING ISSUES IN PRETRANSPLANTATION ASSESSMENT</b> 1. Prioritization for liver transplantation based on MELD score and the pretransplantation evaluation 2. Liver transplantation: Expanding the donor pool 3. Acute liver failure and liver transplantation: Timing and benefit 4. Liver transplantation for hepatocellular carcinoma: Selection and advancements	<b>ARTIFICIAL INTELLIGENCE I</b> 1- The Expanding Role of AI in Healthcare: From Global Applications to Liver Disease Diagnostics 2- Challenges in Health Data Collection for AI: Ethical and Technical Perspectives 3- Patient Outcome Prediction and Management for Liver Cirrhosis with AI: Diagnosis ve Patient Management/Outcome 4- AI technologies in advancing healthcare 5- Multimodal Medical Data Integration in AI-Driven Clinical Research: A Comprehensive Dataset Analysis	<b>GETTING CLOSER WITH MAFLD AS A GLOBAL DISEASE</b> 1. The spectrum of MAFLD: short enough to raise interest, long enough to cover everything 2. Current concepts about the Pathophysiology of MAFLD 3. Risk factors for MAFLD : Let the guilty rise up! 4. Steatotic liver disease:Is the devil in the microbiota?	<b>LIVER ULTRASOUND HANDS-ON TEACHING COURSE</b>	
15:10-15:30	BREAK							
15:30-17:00	<b>HEPATITIS B</b> 1. New Biomarkers 2. What's new in the guidelines for HBV 3. Management of hepatitis B: Aiming for functional cure by conventional or new treatment approaches 4. Discussion	<b>BASIC SCIENCES II</b> 1. Epigenetic mechanisms in HCC 2. Mechanisms of HBV/HDV infection 3. Liver Models in Drug Development 4. Protein Kinase Inhibitors in HCC treatment	<b>ENDO-HEPATOLOGY LIVE DEMONSTRATIONS</b> <b>SESSION II: Liver biopsy by EUS</b> 1. Biliary drainage by EUS in Malignant cases 2. Biliary drainage by EUS in Benign cases 3. Management of post-transplant biliary strictures 4. Management of indetermined biliary strictures 5. Novel methods in Endohepatology	<b>LIVER TRANSPLANTATION: POST-TRANSPLANT COMPLICATIONS AND MORTALITY</b> 1. Evaluation of the living liver donor candidate, surgical technique and outcomes 2. Management of biliary complications in recipients of living donor liver transplantation 3. Immunosuppression strategies in liver transplantation: Minimalization of immunosuppression; rejection and immunomodilation 4. Post-transplantation long-term methabolic challenges and considerations	<b>ARTIFICIAL INTELLIGENCE II</b> <b>Presentations to be followed up with demonstrations</b> 1. Liver Disease Risk Prediction Calculator 2. AI-Based Fibrosis Stage Estimator 3. Hepatocellular Carcinoma (HCC) Early Detection Assistant 4. How can artificial intelligence assist in the differential diagnosis between dysplastic nodules and HCC (Hepatocellular Carcinoma) that develop in patients with liver cirrhosis	<b>MULTIFACETED ASPECTS OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE</b> 1. Met-ALD and MAFLD : A Deadly match 2. Type 2 Diabetes and MAFLD : The Chicken and The egg problem ? 3. Non invasive tests and prognostic markers in MAFLD 4. Imaging for case finding and monitoring of MAFLD	<b>LIVER STIFMENT MEASUREMENT HANDS-ON TEACHING COURSE</b>	
17:00-17:10	BREAK							
17:10-18:30	<b>HEPATITIS D AND C</b> 1. Epidemiology and natural history of chronic hepatitis D- less severe today? 2. Management of hepatitis D today and with new treatments to come 3. Management of hepatitis C- any difficult to treat patients left? 4. Viral Hepatitis and HIV 5. Discussion	<b>BASIC SCIENCES III</b> 1. Metagenomics of healthy and diseased liver 2. Liver aging, accelerating and decelerating factors 3. Hepatic stellate cells 4. Cellular Neighborhoods and signaling	<b>LIVE DEMONSTRATION FROM ENDOSCOPY SUIT</b>	<b>LIVER TRANSPLANTATION: RARE CASES</b> 1. Management of biliary stricture in an adult recipient with situs inversus totalis: Case report 2. Management of post-transplant HCC recurrence: Case report 3. Management of early complications of donor hepatectomy: Case report 4. Discussion	<b>ARTIFICIAL INTELLIGENCE III</b> <b>Continues with demonstrations from the previous session</b> 1. Liver Disease Risk Prediction Calculator 2. AI-Based Fibrosis Stage Estimator 3. Hepatocellular Carcinoma (HCC) Early Detection Assistant 4. How can artificial intelligence assist in the differential diagnosis between dysplastic nodules and HCC (Hepatocellular Carcinoma) that develop in patients with liver cirrhosis	<b>APPROACH TO THE MANAGEMENT OF MAFLD: PAST ACHIEVEMENTS AND FUTURE EXPECTATIONS</b> 1. Updated definitions & guidelines 2. Pathogenesis of MAFLD 3. The role and contributions of MRI-based fat quantification techniques and MR elastography in MAFLD 4. CT based quantitative evaluation of hepatic steatosis	<b>LIVER VASOMIX HANDS-ON TEACHING COURSE</b>	



**22-25 April 2026**  
**İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye**  
**[www.apasI2026istanbul.org](http://www.apasI2026istanbul.org)**



## PRELIMINARY SCIENTIFIC PROGRAM

**THURSDAY, 23 APRIL 2026**

LEGEND >>	PLENARY SESSIONS	SCIENTIFIC SESSIONS	PRE-CONGRESS WORKSHOPS	SATELLITE SYMPOSIA	ABSTRACT SESSIONS	GENERAL & SOCIAL		
Time / Room	MAIN HALL 1	HALL 2	HALL 3	HALL 4	HALL 5	HALL 6	HALL 7	HALL 8
8:00-9:00	<b>Meet The Expert</b> Wilson’s disease: when to suspect and how to diagnose difficult cases	<b>Meet The Expert</b> Hemochromatosis in West and East	<b>Meet The Expert</b> Lipid metabolism derangement and Liver	<b>Meet The Expert</b> Gaucher’s Disease in Adults	<b>Meet The Expert</b> Involvement of Liver in Cystic Fibrosis	<b>Meet The Expert</b> AAT Deficiency: Diagnosis and Management	<b>Meet The Expert</b> Lipid Storage Diseases	
9:00-10:30	<b>HEPATITIS B</b>  1. Consensus and Controversy of Functional Cure for hepatitis B  2. Immunological Insights into Functional Cure  3. Virological insights into functional Cure  4. MicroRNA and Antisense Oligonucleotides in Hepatitis B functional Cure	<b>GENETIC AND METABOLIC DISEASES PRESENTING IN ADULTHOOD</b>  1. Intrahepatic Cholestasis  2. Organomegaly  3. Genetic and Metabolic Diseases Associated with Hepatic Steatosis  4. Genetic and Metabolic Diseases Associated with Hepatic Mass Formation	<b>ACUTE LIVER FAILURE</b>  1. Current approach to the treatment of acute liver failure  2. Gene-Edited Pig Livers as Temporary Support  3. mRNA-Based Liver Regeneration 3D Bioprinted Human Liver Models  4. Expanded Liver Transplantation Criteria	<b>ALCOHOL &amp; LIVER</b>  1. Improved Diagnostics and Biomarkers in alcohol related liver diseases (ALD)  2. Role of the Gut–Liver Axis and Microbiome in ALD  3. Management and Prognosis of ALD  4. Alcohol Use Disorder (AUD) Management	<b>HEPATOLOGY FORUM</b>  THE LIVER FORUM: FACILITATING DRUG DEVELOPMENT FOR THE TREATMENT OF LIVER DISEASE	<b>ACLF-AARC JOINT MEETING I</b>	<b>WOMEN IN HEPATOLOGY</b>  1. Women as hepatologists: Competitive and innovative  2. Barriers and challenges women face in endo-hepatology training  3. Equal opportunity for funding in research and authorship in hepatology  4. Networking and mentoring :Prerequisites for promoting women's leadership in hepatology	<b>YOUNG INVESTIGATORS WORKSHOP AASLD-APASL</b>
10:30-10:50	BREAK							
10:50:11:20	OPENING CEREMONY							
11:20-11:45	OPENING LECTURE							
11:45-12:10	PRESIDENTIAL LECTURE  Hydatid Disease							
12:10-13:40	BREAK							
12:30-13:30	SATELLITE SYMPOSIA Simultaneously in parallel halls							
13:40:15:10	<b>ART LECTURES &amp; CASE REPORTS</b>  1. Case report on HCC  2. Art Lecture  3. Case report on MAFLD  4. Art Lecture	<b>PAEDIATRIC TRANSPLANTATION I</b>  1. Rare Indications and Special Considerations Metabolic Liver Diseases and Transplantation Strategies  2. Pediatric Liver Transplantation for Metabolic Disorders: Expanding Indications and Improving Outcomes  3. Innovations in the Management of Pediatric Metabolic Liver Diseases  4. Advances in Gene Therapy and Liver Transplantation for Metabolic Disorders	<b>AUTOIMMUNE HEPATITIS I</b>  1. Surveillance for cholangiocarcinoma and management of PSC-related malignancies  2. Ig4 related hepatobiliary disorders- diagnosis and treatment  3. Quality of life in autoimmune liver diseases (AIH,PBC and PSC)  4. The treatment of autoimmune diseases with biologic agents	<b>INCIDENTAL LIVER LESIONS</b>  1. Scope of the problem  2. Cost-effective and patient-friendly approach  3. When to perform biopsy  4. Pathologist’s perspective	<b>HEPATOLOGY FORUM HBV OVERVIEW</b>	<b>ACLF-AARC JOINT MEETING II</b>	<b>CIRRHOSIS I</b>  1. Cell to Cell interaction in liver and its role in choronic liver disease pathogenesis  2. Molecular and cellular mechanisms of liver fibrosis and therapeutic perspectives  3. Optimal strategies for recompensation and prevention to development of HCC after curative treatment in patients with hepatitis C  4. Optimal approach strategies for recompensation in patients with hepatitis B	<b>YOUNG INVESTIGATORS WORKSHOP AASLD-APASL</b>
15:10-15:30	BREAK							



**22-25 April 2026**

**İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye**

**www.apasl2026istanbul.org**



## PRELIMINARY SCIENTIFIC PROGRAM

**THURSDAY, 23 APRIL 2026**

LEGEND >>	PLENARY SESSIONS	SCIENTIFIC SESSIONS	PRE-CONGRESS WORKSHOPS	SATELLITE SYMPOSIA	ABSTRACT SESSIONS	GENERAL & SOCIAL		
Time / Room	MAIN HALL 1	HALL 2	HALL 3	HALL 4	HALL 5	HALL 6	HALL 7	HALL 8
15:30-17:00	<b>HEPATITIS B</b>  1. Mechanism of Covalently Closed Circular DNA (cccDNA)Formation  2. Interplay of HBV RNA and HBs Ag in Hepatitis B virus infection  3. Endosomal and Autophagic Vesicle Pathways in HBV Biogenesis  4. Innate and Adaptive Immunity of HBV Infection	<b>PAEDIATRIC TRANSPLANTATION II</b>  5. Advancements in Minimally Invasive and Robotic-Assisted Pediatric Liver Transplantation  6. Optimizing Vascular and Biliary Reconstruction in Pediatric RecipientsLong-Term Outcomes and Quality of Life  7. Improved Post-Transplant Care and Long-Term Survival in Pediatric Patients  8. Quality of Life and Neurodevelopmental Outcomes After Pediatric Liver Transplantation	<b>AUTOIMMUNE HEPATITIS II</b>  1-Diagnostic approach of AIH  2-Standard and non-standard therapies of AIH  3-Second-line therapies for PBC  4-The role of liver pathology in diagnosis of autoimmune liver diseases (AIH, PBC and PSC)	<b>HEPATOCELLULAR CARCINOMA</b>  1. Molecular & Genomic Advances in HCC  2. Surveillance and Risk Stratification for HCC  3. Immunotherapy advances in HCC  4. AI algorithms now assist in early detection and radiogenomic classification of HCC using multiphase CT/MRI	<b>WHEN DO WE NEED THE INTERVENTIONAL RADIOLOGIST ?</b>  1. Multidisciplinary Case-Based Approaches to the Treatment of HCC  2. TARE in BCLC Stage B/C HCC  3. TAKE in BCLC Stage B/C HCC  4. Innovative Endovascular Approaches in Liver Metastases: ChemoSat and LIOX	<b>ACLF-AARC JOINT MEETING III</b>	<b>CIRRHOSIS II</b>  1. What should be the optimal strategy in the diagnosis and treatment of minimal hepatic encephalopathy  2. What should be the optimal strategy in the treatment of bacterial infection in cirrhotic patients  3. What should be the optimal strategy in the diagnosis and treatment of Portopulmonary syndrome  4. What should be the optimal strategy in the diagnosis and treatment of Hepatopulmonary syndrome	<b>YOUNG INVESTIGATORS WORKSHOP AASLD-APASL</b>
17:00-17:10	BREAK							
17:10-18:30	<b>MENTOR-MENTEE SESSION</b>  Clinical Compass: Navigating Hepatology Through Mentorship Translating Experience into Expertise: Clinical Mentorship in Action  Selected Original case presentations	<b>CURRENT &amp; FUTURE TREATMENTS OF HEPATITIS B</b>  1. Changing trends in hepatitis B treatment  2. Future technologies to improve patient journey with HBV  3. Gene therapies for HBV infection  4. Immune Checkpoint Inhibitors in the functional Cure of Chronic Hepatitis	<b>EMERGING IMMUNE MODULATORS IN AUTOIMMUNE HEPATITIS</b>  1. Epigenetic and microRNA signatures  2. Immune cell "cell in cell" formations (Aventosis)  3. Treg-boosting therapies & low-dose IL 2  4. JAK inhibitors & anti TNF agents	<b>WHAT'S NEW IN BENIGN LIVER TUMORS</b>  1. Improved Molecular Classification of Hepatocellular Adenoma (HCA)  2. Non-Invasive Diagnosis & Surveillance  3. Changing Epidemiology & Risk Factors  4. Pregnancy Considerations. what is new in ultrasound elastography assesment of diffuse and focal liver lesions	<b>MANAGEMENT OF LIVER CIRRHOSIS</b>  1. Use of sedation agents for endoscopic procedures in patients with cirrhosis  2. Use of anticoagulants and antiplatelet agents in liver cirrhosis  3. Preoperative evaluation of cirrhotic diseases and risk determination  4. Liver Cirrhosis and Immunization	<b>ACLF-AARC JOINT MEETING IV</b>	<b>RESEARCH SESSION</b>  1. Niche Areas for Research in Hepatology  2. AI Based Research in Hepatology  3. "Omics" in Liver Disease Research  4. Research in Hepatology: Insprition; Perspiration or both	<b>YOUNG INVESTIGATORS WORKSHOP AASLD-APASL</b>
18:30-19:30	SATELLITE SYMPOSIA Simultaneously in parallel halls							



**FRIDAY, 24 APRIL 2026**

LEGEND >>	PLENARY SESSIONS	SCIENTIFIC SESSIONS	PRE-CONGRESS WORKSHOPS	SATELLITE SYMPOSIA	ABSTRACT SESSIONS	GENERAL & SOCIAL		
Time / Room	MAIN HALL 1	HALL 2	HALL 3	HALL 4	HALL 5	HALL 6	HALL 7	HALL 8
8:00-9:00	Meet The Expert Hepatic Encephalopathy	Meet The Expert Porto Pulmonair and Hepato-pulmonaire Syndrome		Meet The Expert HCV & HBV	Meet The Expert HDV	Meet The Expert MAFLD	Meet The Expert Alcoholic Hepatitis	
9:00-10:30	APASL - CHESS JOINT MEETING  1. AI (CHESS)  2. Vasomics (CHESS)  3. Screening and new treatments of liver fibrosis (APASL)  4. Emerging Pharmacotherapies in portal hypertension APASL)	APASL-ELITA JOINT MEETING  LIVER TRANSPLANTATION IN THE ERA OF MAFLD: CHALLENGES AND FUTURE PERSPECTIVES (ELITA)  1. The rise of MASLD in cirrhosis liver transplant indications: epidemiology and evolution  2. The role of psychosocial assessment: behavioral, lifestyle and ethical considerations  3. Post-Transplant Outcomes and Recurrence of MASLD: prevention and management  4. Tailoring immunosuppression for Liver Transplant Recipients with MASLD	NON-CIRRHOTIC PORTAL HYPERTENSION / IDIOPATIC PORTAL HYPERTENSION  1. The spectrum of PSVD  2. Influence of Gut Microbiome in PSVD  3. Metabolomic Profiling of PSVD  4. Imaging Techniques for PSVD	PREGNANCY AND LIVER  1. Pregnancy in patients with pre-existing liver disease  2. ICP-HELLP  3. PRE_ECLAMPسيا / ECLAMPسيا  4. AFLP	ARTIFICIAL INTELLIGENCE  1. Artificial Intelligence in Liver Surgery and Transplantation  2. Advancing AI-based healthcare through vision language models: Imaging techniques and applications in liver disease  3. Prediction of outcomes of Liver transplantation using AI  4. Use of Artificial Intelligence in Liver Surgery and Transplantation	ROLE OF IMAGING IN LIVER DISEASES  1. Evaluation of liver malignant tumors with PET/MRI after locoregional treatment  2. Imaging evaluation of living donor candidates: analysis of liver volume and anatomy with CT  3. Impact of liver specific contrast agents in the differential diagnosis of liver masses  4. Sensitivity of imaging in diffuse liver diseases	CIRRHOSIS OUTSIDE THE LIVER: WHERE TO DROP THE ANCHOR?  1. The heart in liver disease  2. The kidney in liver disease  3. The lungs in liver disease  4. Sarcopenia in patients with liver cirrhosis	ABSTRACT SESSION
10:30-10:50	BREAK							
10:50 - 12:10	APASL -AASLD JOINT MEETING  GENETICS IN DIAGNOSIS AND CARE MANAGEMENT IN LIVER DISEASES ACROSS THE LIFESPAN  1. MASLD Genetics globally and the implications for natural history  2. Treatment options for cholestatic diseases based upon genetics  3.Wilson disease in India and globally  4. MASLD genetics and the impact upon natural history around the globe	ABSTRACT SESSION	ABSTRACT SESSION	ABSTRACT SESSION	ABSTRACT SESSION	ABSTRACT SESSION	ABSTRACT SESSION	ABSTRACT SESSION
12:10-13:40	BREAK							
12:30-13:30	SATELLITE SYMPOSIA Simultaneously in parallel halls							





**FRIDAY, 24 APRIL 2026**

LEGEND >>	PLENARY SESSIONS	SCIENTIFIC SESSIONS	PRE-CONGRESS WORKSHOPS	SATELLITE SYMPOSIA	ABSTRACT SESSIONS	GENERAL & SOCIAL		
Time / Room	MAIN HALL 1	HALL 2	HALL 3	HALL 4	HALL 5	HALL 6	HALL 7	HALL 8
13:40-15:10	<b>APASL - EASL JOINT MEETING</b>  CHALLENGES IN MANAGEMENT OF ACUTE LIVER INJURY IN THE CRITICALLY ILL PATIENT  1. Sepsis induced liver injury: recent mechanistic insights  2. Clinical presentation and treatment of systemic infections affecting the liver  3. ICU management of ischemic hepatitis  4. Prognosis and the role of liver transplantation in ischemic liver failure  Discussion	<b>APASL-ISLS JOİNT MEETING 2026.</b>  1. Targeted Therapies in the Era of Precision Medicin  2. How do we define Resectability in Liver Cancer Surgery in 2026  3. Downstaging in HCC using immuno-oncological treatments for Surgery and Transplantation  4. Current updates in Klatskin tumor surgery	<b>LIVER CIRRHOSIS</b>  1. Ultrasound fusion imaging: clinical applications in liver diseases  2. Use of endosonography in liver diseases: an update  3. Evaluation and treatment of cirrhotic patients with portal vein thrombosis  4. Non Invasive and invasive Assesment of Portal Hypertension  Discussion	<b>AHOC Study Meeting</b>  HCC Study	<b>EMERGING THERAPIES IN DEVELOPMENT OF HBV</b>  1. Entry inhibitors (e.g., bulevirtide)  2. siRNA/antisense oligonucleotides (e.g., VIR-2218, JNJ-3989)  3. Capsid assembly modulators (CAMs)  4. Immune modulators (e.g., toll-like receptor agonists, checkpoint inhibitors)	<b>LIVER CIRRHOSIS</b>  1. Nutritional Assesment of Cirrhotic Patient  2. Treatment of Sarcopenic Obesity  3. The Role of Microbiome in the Liver Cirrhosis: Current and Future Microbiome Targeted Therapeutic  4. Hepatic nodule in liver cirrhosis: Is more scrutiny necessary ?	<b>HEPATITIS DELTA VIRUS</b>  1. Bulivertide  2. Monoclonal anti body trials and therapies  3. NAPS  4. Future of the HDV therapies	<b>ABSTRACT SESSION</b>
15:10-15:30	BREAK							
15:30-17:00	<b>APASL-ALEH JOINT MEETING</b>	<b>APASL-ILTS JOINT MEETING</b>  1. Current Status of Xenotransplantation  2. Role of machine perfusion in marginal grafts in liver transplantation  3. Evidence-based Management of Small-for-Size Syndrome in LDLT  4. Utilization of marginal donors in living donor liver transplantation, (metabolic syndrome, steatosis, borderline FLR )	<b>PORTAL HYPERTENSION</b>  1. Changing paradigm in the terminology  2. Pathophysiology: What we have learned so far  3. Left sidedportal hypertension: Diagnosis and management  4. Emerging treatments	<b>CHALLENGES IN METABOLIC LIVER DISEASES</b>  1. Wilson’s disease: when to suspect and how to diagnose difficult cases  2. Hemochromatosis in West and East  3. Gaucher’s Disease in adults  4. AAT Deficiency: Diagnosis and management	<b>UPDATE AND REPORTS FROM THE COUNTRIES AND THE REGIONS I</b>  <i>Epidemiology of HBV and HCV infections in</i>  1. Bangladesh 2. India 3. Korea 4. Mongolia 5. Pakistan 6. Taiwan 7. Thailand 8. Türkiye	<b>VIRAL HEPATITIS II</b>  1. Gene Editing and Therapeutic Vaccine for hepatitis B  2. The role and Prognosis of Glucocorticoids in the treatment of Liver Failure  3. The Role of Microbiome in the Liver Cirrhosis: Current and Future Microbiome Targeted Therapeutics  4. Elimination of viral hepatitis worldwide	<b>GENDER DIFFERENCES IN LIVER DISEASES</b>  1. Epidemiology and natural history of chronic liver diseases with respect to gender  2. Gender differences in liver fibrosis  3. Why are women more vulnerable to alcohol?  4. Sexual dimorphism in MAFLD and MAFLD associated HCC	<b>ABSTRACT SESSION</b>
17:00-17:10	BREAK							
17:10-18:30	<b>AWARD SESSION</b>	<b>APASL- SOLDA JOINT MEETING</b>	<b>MANAGEMENT OF COMPLICATIONS OF LIVER CIRRHOSIS AND RATIONAL DRUG USE</b>  1. What is new for the treatment of Ascites  2. What is new for the treatment of Hepatorenal Syndrome  3. What is new for the treatment of Hepatic Encephalopatý  4. What is new for the treatment of Variceal Bleeding	<b>EDITORS FORUM</b>  1. Hepatology  2. Hepatology International  3. Journal of Hepatology  4. GUT	<b>CONCEPTUAL SHIFT: FROM “ALCOHOLIC HEPATITIS” TO “ALCOHOL-ASSOCIATED HEPATITIS” (AAH)</b>  1. New definitions and Biomarkers  2. Therapeutic Advances  3. Prognosis and Long-Term Management  4. Liver Transplantation in acute alcohol related hepatitis	<b>DIVING DEEP IN PHT</b>  1. Regression of fibrosis and portal hypertension: clinical evidence and underlying mechanisms  2. Inflammation in chronic liver disease: pathogenic mechanism and therapeutic opportunity  3. Role of sinusoidal cells in the pathogenesis and treatment of chronic liver disease  4. Vascular pathobiology as key underlying mechanism and theranostic option in liver diseases	<b>AUTOIMMUNE LIVER DISEASE</b>  1. Immunopathogenesis of autoimmune hepatitis  2. Advances in the management of primary biliary cholangitis, primary sclerosing cholangitis  3. Emerging Therapies in AIH  4. Cessation or life long treatment in AIH	<b>ABSTRACT SESSION</b>
18:30-19:30	SATELLITE SYMPOSIA Simultaneously in parallel halls							



LEGEND >>	PLenary Sessions	Scientific Sessions	Pre-congress Workshops	Satellite Symposia	Abstract Sessions	General & Social		
Time / Room	Main Hall 1	Hall 2	Hall 3	Hall 4	Hall 5	Hall 6	Hall 7	Hall 8
8:00-9:00	Meet The Expert Autoimmune Diseases	Meet The Expert Acute Liver Failure	Meet The Expert ACLF	Meet The Expert HCC		Meet The Expert Budd-Chiari syndrome	Meet The Expert Portal Hypertension	Meet The Expert DILI
9:00-10:30	<b>HEPATITIS B</b>  1. What do the revised guidelines say about the treatment of HBV infection  2. Future gene therapies for HBV infection  3. Future technologies to improve patient journey with HBV  4. Future research areas in HBV	<b>ALCOHOL-ASSOCIATED LIVER DISEASE(ALD)</b>  1. Pathophysiology of alcoholic liver diseases  2. New markers for the diagnosis of alcoholic liver diseases  3. Standart treatments of alcoholic liver diseases  4. Emerging treatments of alcoholic treatments	<b>HCV</b>  1. Improved Screening Recommendations  2. Advances in Treatment  3. Focus on Microelimination  4. Extrahepatic Manifestations, Comorbidities and Treatment outcomes of extrahepatic manifestations	<b>MULTI-FACETED ASPECTS OF PORTAL HYPERTENSION</b>  1. Non-invasive assessments of hepatic fibrosis and portal hypertension  2. Invasive assessments of hepatic fibrosis and portal hypertension  3. Molecular basis of portal hypertension therapy  4. Diagnosis and management of portal-hypertensive gastro enteropathy and GAVE syndrome	<b>COMPLICATIONS OF CIRRHOSIS</b>  1. Current approaches to the management of ascites  2. Current management of hepatorenal syndrome  3. Management of hepatic encephalopathy in cirrhosis  4. Spontaneous bacterial peritonitis: What do current guidelines advise?	<b>ACUTE LIVER FAILURE</b>  1. Enhanced Supportive Care: Continuous Renal Replacement Therapy(CRRT) & Plasma Exchange  2. Artificial & Bioartificial Liver Devices  3. Cell & Stem Cell Transplantation  4. Regenerative Biotechnologies & mRNA	<b>DRUG AND HERBAL INDUCED LIVER INJURY</b>  1. Epidemiology of DILI and HILI  2. Mechanisms of DILI and HILI  3. Clinical spectrum of DILI and HILI  4. Treatment and prognosis of DILI and HILI	<b>DILI &amp; HILI I</b>
10:30-10:50	BREAK							
10:50 - 12:10	<b>ART LECTURES &amp; CASE REPORTS</b>  1. Case report on HBV  2. Art Lecture  3. Case Report on HDV  4. Art Lecture	<b>ABSTRACT SESSION</b>	<b>ABSTRACT SESSION</b>	<b>ABSTRACT SESSION</b>	<b>ABSTRACT SESSION</b>	<b>ABSTRACT SESSION</b>	<b>ABSTRACT SESSION</b>	<b>DILI &amp; HILI II</b>
12:10-13:40	BREAK							
12:30-13:30	SATELLITE SYMPOSIA Simultaneously in parallel halls							
13:40:15:10	<b>METABOLIC ASSOCIATED FATTY LIVER DISEASE</b>  1. Updated definitions & guidelines  2. Emerging therapies on the horizon  3. Pharmacotherapy breakthroughs  4. AI-enhanced clinical trials	<b>AI IN PREVENTION AND EARLY DIAGNOSIS OF LIVER DISORDERS</b>  1. AI in screening liver diseases primary care	<b>THE LIVER IN SYSTEMIC DISEASE</b>  1. Systemic Lupus Erythematosus (SLE) and Liver Involvement  2. The Liver in hematologic disorders  3. Thyroid and liver  4. Ging and Aging -Related senescence in Liver	<b>SCREENING LIVER FIBROSIS</b>  1. AI-Enhanced Ultrasound Elastography  2. FIB-Net Algorithm and Cascade Model for Steatosis Staging  3. Magnetic Resonance Elastography (MRE) and Shear Wave Elastography (SWE)  4. Radiomics and Machine Learning	<b>VARICEAL BLEEDING</b>  1. Endoscopic Ultrasound (EUS)-Guided Therapies  2. Shortened Vasoconstrictor Therapy Post-Endoscopic Variceal Ligation (EVL)  3. Preemptive TIPS for High-Risk Patients  4. What to do in recurrent variceal bleed. TIPS or BRTO or both	<b>WHAT IS NEW IN HEPATIC BILIARY DUCTAL DISEASES</b>  1. Bile Duct Organoids  2. Bile Duct-on-a-Chip  3. Endoscopic Imaging  4. Bioabsorbable Bile Duct Substitutes	<b>UPDATE AND REPORTS FROM THE COUNTRIES AND THE REGIONS II</b>	<b>DILI &amp; HILI III</b>
15:10-15:30	BREAK							



35<sup>TH</sup> ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

22-25 April 2026

İstanbul Lütfi Kırdar International Convention and Exhibition Centre • İstanbul / Türkiye

www.apasl2026istanbul.org



PRELIMINARY

SCIENTIFIC PROGRAM

SATURDAY, 25 APRIL 2026

LEGEND >>	PLENARY SESSIONS	SCIENTIFIC SESSIONS	PRE-CONGRESS WORKSHOPS	SATELLITE SYMPOSIA	ABSTRACT SESSIONS	GENERAL & SOCIAL		
Time / Room	MAIN HALL 1	HALL 2	HALL 3	HALL 4	HALL 5	HALL 6	HALL 7	HALL 8
15:30-17:00	<div>DEBATES</div> <div>1. MAFLD or MASLD?</div> <div>2. COAGULATION or ANTICOAGULATION in liver cirrhosis</div> <div>3. TIPS or BRTO in recurrent gastric varices</div> <div>4. Treat everyone with HBV or treat according to guidelines</div>	<div>CURRENT AND FUTURE MANAGEMENT OF MAFLD</div> <div>1. A palatable, Affordable Diet and Applicable Exercise Program in Steatotic Liver Disease</div> <div>2. Treatment in MAFLD : More Than Diet and Exercise</div> <div>3. Emerging Therapies on the Horizon</div> <div>4. AI-enhanced Clinical Trials</div>	<div>ACUTE ON CHRONIC LIVER FAILURE</div> <div>1. Terminology of ACLF in the East and the West</div> <div>2. Immunopathogenesis of ACLF</div> <div>3. Clinical spectrum of ACLF</div> <div>4. Treatment of ACLF</div>	<div>ENDOHEPATOLOGY I: NONINTERVENTIONAL DIAGNOSTIC PROCEDURES</div> <div>1. Endoscopic Ultrasound guided ERCP</div> <div>2. Endoscopic Ultrasound Doppler Assessment</div> <div>3. Endoscopic Ultrasound Tissue Stiffness Assessment</div> <div>4. Endoscopic Ultrasound Biliary Assessment</div>	<div>CURRENT TOOLS IN THE EVALUATION OF LIVER FAT AND STIFFNESS</div> <div>1. New next-gen fibroscan application</div> <div>2. Ultrasound guided fat quantification, current techniques and clinical applications</div> <div>3. What is new in ultrasound elastography assesment of diffuse and focal liver lesions</div> <div>4. Ultrasound fusion imaging: clinical applications in liver diseases</div>	<div>METABOLIC ASSOCIATED FATTY LIVER DISEASE</div> <div>1. New MAFLD nomenclature</div> <div>2. New insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD)</div> <div>3. Screening for MAFLD: who, when and how?</div> <div>4. New pharmacological treatment options for MAFLD</div>		<div>DILI &amp; HILI IV</div>
17:00-17:10	BREAK							
17:10-18:30	<div>GLOBAL SUMMIT</div>			<div>ENDOHEPATOLOGY II: INTERVENTIONAL PROCEDURES</div> <div>1. Endoscopic Ultrasound-Guided Liver Biopsy and Portal Venous Blood Sampling</div> <div>2. Portal Pressure Measurement Under Endoscopic Ultrasound Guidance</div> <div>3. Endoscopic Ultrasound-Guided treatment of gastric varices</div> <div>4. Endoscopic Ultrasound-Guided Biliary drainage</div>	<div>ADVANCES IN THE ASSESMENT AND PROGRESS OF LIVER DISEASE</div> <div>1. MR PDFF Evaluation of Steatotic Liver</div> <div>2. Spleen Stiffness in the follow up of Portal Hypertension</div> <div>3. Shear Wave Elastography (SWE)</div> <div>4. AI-Enhanced Non-Contrast CT Imaging</div>	<div>FECAL MICROBIOTA TRANSPLANTATION</div> <div>1. Fecal Microbiota transplantation in MAFLD</div> <div>2. FMT in Liver cirrhosis</div> <div>3. FMT in HCC</div> <div>4. Research Progress of Fecal Microbiota Transplantation in Liver Diseases</div>		<div>DILI &amp; HILI V</div>
18:30-19:30	<div>CLOSING CEREMONY</div>							